Literature DB >> 28229620

Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea.

Hatice Resorlu1, Sevilay Kılıc2, Selda Isık2, Ferhat Gokmen1.   

Abstract

The patient in this report was diagnosed simultaneously with primary biliary cirrhosis (PBC), spondyloarthritis, and generalized morphea and was started on infliximab therapy. In addition to an improvement in clinical symptoms with this therapy, an improvement was also observed in laboratory parameters such as cholestatic enzymes, C-reactive protein, and erythrocyte sedimentation rate. Infliximab was well tolerated in this 56-year-old patient. However, further studies must be performed in order to clarify the therapeutic role of TNF-α blockers in, PBC and generalized morphea.

Entities:  

Keywords:  Generalized morphea; Infliximab; Primary biliary cirrhosis; Spondyloarthritis

Mesh:

Substances:

Year:  2017        PMID: 28229620     DOI: 10.1080/17843286.2017.1290567

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  1 in total

1.  Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab.

Authors:  Danya Traboulsi; Elzbieta A Kaminska; Susan G Barr; Charlene Hunter; P Regine Mydlarski
Journal:  JAAD Case Rep       Date:  2018-09-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.